Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 225

1.

The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.

Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R.

J Clin Psychiatry. 2009 Mar;70(3):318-25. Epub 2008 Dec 16.

PMID:
19192469
2.

A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.

Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD.

J Clin Psychiatry. 2008 Jul;69(7):1046-56.

PMID:
18605811
3.

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.

McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH.

J Clin Psychiatry. 2004;65 Suppl 18:47-56.

PMID:
15600384
4.

Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.

Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD.

Psychopharmacology (Berl). 2006 Dec;189(2):259-66. Epub 2006 Oct 21.

PMID:
17058105
5.

Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.

L'Italien GJ, Casey DE, Kan HJ, Carson WH, Marcus RN.

J Clin Psychiatry. 2007 Oct;68(10):1510-6.

PMID:
17960964
6.

Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.

Wang LJ, Ree SC, Huang YS, Hsiao CC, Chen CK.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:260-6. doi: 10.1016/j.pnpbp.2012.10.010. Epub 2012 Oct 18.

PMID:
23085073
7.

Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine.

Newcomer JW, Meyer JM, Baker RA, Eudicone JM, Pikalov A, Vester-Blokland E, McQuade RD, Crandall DT, Carson WH, Marcus RN, L'italien G.

Schizophr Res. 2008 Dec;106(2-3):300-7. doi: 10.1016/j.schres.2008.09.002. Epub 2008 Oct 29.

8.

Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.

Stauffer VL, Sniadecki JL, Piezer KW, Gatz J, Kollack-Walker S, Hoffmann VP, Conley R, Durell T.

BMC Psychiatry. 2010 Nov 3;10:89. doi: 10.1186/1471-244X-10-89.

9.

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).

Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA; Schizophrenia Trials Network.

Am J Psychiatry. 2011 Sep;168(9):947-56. doi: 10.1176/appi.ajp.2011.10111609. Epub 2011 Jul 18.

10.

Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.

Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC.

J Clin Psychopharmacol. 2009 Apr;29(2):165-9. doi: 10.1097/JCP.0b013e31819a8dbe.

11.

Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.

Mukundan A, Faulkner G, Cohn T, Remington G.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006629. doi: 10.1002/14651858.CD006629.pub2. Review.

PMID:
21154372
12.

The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.

Lee NY, Kim SH, Jung DC, Kim EY, Yu HY, Sung KH, Kang UG, Ahn YM, Kim YS.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jul 1;35(5):1273-8. doi: 10.1016/j.pnpbp.2011.03.022. Epub 2011 Apr 14.

PMID:
21513765
13.

A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.

Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH.

Biol Psychiatry. 2009 Mar 15;65(6):510-7. doi: 10.1016/j.biopsych.2008.07.033. Epub 2008 Nov 4.

PMID:
18986646
14.

Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review.

Spurling RD, Lamberti JS, Olsen D, Tu X, Tang W.

J Clin Psychiatry. 2007 Mar;68(3):406-9.

PMID:
17388710
15.

Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.

Jin H, Shih PA, Golshan S, Mudaliar S, Henry R, Glorioso DK, Arndt S, Kraemer HC, Jeste DV.

J Clin Psychiatry. 2013 Jan;74(1):10-8. doi: 10.4088/JCP.12m08001. Epub 2012 Nov 27.

16.

A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.

Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer VL, Watson SB, Breier A.

J Clin Psychiatry. 2009 Apr;70(4):572-81. Epub 2009 Mar 24.

PMID:
19323965
17.

Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial.

Kemp DE, Calabrese JR, Tran QV, Pikalov A, Eudicone JM, Baker RA.

J Clin Psychiatry. 2010 Sep;71(9):1138-44. doi: 10.4088/JCP.09m05159gre. Epub 2010 May 4.

18.

Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.

Almandil NB, Liu Y, Murray ML, Besag FM, Aitchison KJ, Wong IC.

Paediatr Drugs. 2013 Apr;15(2):139-50. doi: 10.1007/s40272-013-0016-6. Review.

PMID:
23519708
19.

Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia.

Ascher-Svanum H, Stensland MD, Peng X, Faries DE, Stauffer VL, Osuntokun OO, Kane JM.

Curr Med Res Opin. 2011 Jan;27(1):115-22. doi: 10.1185/03007995.2010.537594. Epub 2010 Nov 26.

PMID:
21110749
20.

Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine.

Brown RR, Estoup MW.

Int Clin Psychopharmacol. 2005 Mar;20(2):105-12.

PMID:
15729087
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk